Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Stock news
InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ: INM) (TSX: IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), today announced top-line results from its 755-102-HV Phase 1 clinical trial ("Study 102").
VANCOUVER, BC, Jan. 5, 2021 /CNW/ - InMed Pharmaceuticals Inc.
OTTAWA, ON, Dec. 10, 2020 /CNW/ -Note: All times localOttawa, Ontario Private meetings.
TSX:IN NASDAQ:INM \\- Initial application with INM-088 to treat ocular disease -VANCOUVER, BC, Dec. 3, 2020 /CNW/ - InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ: INM) (TSX: IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol ("CBN"), today announced top-line results from its 755-101-HV Phase 1 clinical trial ("Study 101").
VANCOUVER, BC, Nov. 24, 2020 /CNW/ - InMed Pharmaceuticals Inc.
VANCOUVER, BC, Nov. 18, 2020 /CNW/ - InMed Pharmaceuticals Inc.
NEW YORK, Nov. 17, 2020 /CNW/ -- Global travel authority Lonely Planet has today unveiled a radical reimagining of its much-awaited Best in Travel picks for 2021, reflecting an unprecedented year of disruption in the travel industry.
InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ: INM) (TSX: IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the clinical development of cannabinol (CBN), today announced that it has closed the previously announced public offering of common shares, together with accompanying warrants.